**Proteins** 

# **Screening Libraries**

# WEE1-IN-5

Cat. No.: HY-147054 CAS No.: 2243882-74-6 Molecular Formula:  $C_{26}H_{28}Cl_{2}N_{6}O$ Molecular Weight: 511.45 Target: Wee1; CDK

Pathway: Cell Cycle/DNA Damage

Storage: Powder -20°C 3 years

2 years

-80°C In solvent 6 months

> -20°C 1 month

**Product** Data Sheet

## **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 20 mg/mL (39.10 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.9552 mL	9.7761 mL	19.5523 mL
	5 mM	0.3910 mL	1.9552 mL	3.9105 mL
	10 mM	0.1955 mL	0.9776 mL	1.9552 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1 mg/mL (1.96 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 1 mg/mL (1.96 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1 mg/mL (1.96 mM); Clear solution

# **BIOLOGICAL ACTIVITY**

Description	WEE1-IN-5 is a potent WEE1 inhibitor with an IC <sub>50</sub> value of 0.8 nM. WEE1-IN-5 inhibits phospho-CDC2. WEE1-IN-5 abrogates the G2 check point, increasing sensitivity to DNA damaging agents in cancer cells. WEE1-IN-5 can be used for researching anticancer <sup>[1]</sup> .
IC <sub>50</sub> & Target	IC <sub>50</sub> : 0.8 nM (WEE1), 188 nM (CDC2) <sup>[1]</sup>

In Vitro WEE1-IN-5 exhibits an EC $_{50}$  of 188 nM in pCDC2 and an IC $_{50}$  shift for CYP3A4/5 $^{[1]}$ .

	MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	WEE1-IN-5 (5mg/kg for PO; 1 mg/kg for IV; single dosage) exhibits a CL of 14 mL/min/kg, an AUC <sub>int</sub> 1324 h·ng/mL and bioavailability of 35% in SD rats <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **REFERENCES**

[1]. H. Gelderblom, et al. 601TiP First-in-human phase I study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced solid tumours. Ann Oncol. 2020 Sep; 31: S501-S502.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com